e-Therapeutics plc Change of Adviser (5948Q)
March 01 2021 - 2:00AM
UK Regulatory
TIDMETX
RNS Number : 5948Q
e-Therapeutics plc
01 March 2021
e-therapeutics plc
("e-therapeutics" or the "Company")
Change of Adviser
Oxford, UK, 1 March 2021 - e-therapeutics plc (AIM: ETX) is
pleased to announce the appointment of SP Angel Corporate Finance
LLP as the Company's Nominated Adviser and Broker, with immediate
effect.
Director Disclosure
The Company also announces the following additional information
in accordance with paragraph (g) of Schedule Two to the AIM Rules
for Companies in respect of Ali Mortazavi, CEO of the Company. Mr
Mortazavi is a current LLP Member of Arcade Films 4 LLP and was at
the time of his appointment to the Board on 11 February 2020.
Enquiries:
e-therapeutics plc
Ali Mortazavi, CEO Tel: +44 (0)1993 883
125
www.etherapeutics.co.uk
SP Angel Corporate Finance LLP Tel: +44(0)20 3470
0470
Nominated Adviser and Broker
Matthew Johnson/Caroline Rowe (Corporate
Finance)
Vadim Alexandre/Rob Rees (Corporate Broking)
About e-therapeutics plc
e-therapeutics plc is an Oxford, UK-based company with a
powerful computer-based approach to drug discovery, founded on its
industry-leading expertise in network biology to fully capture
disease complexity. The Company combines network science, machine
learning, artificial intelligence, statistics and big data with
expertise in drug discovery and development to transform the search
for new medicines and intervention strategies.
e-therapeutics has developed an in silico laboratory that
enables the rapid screening of millions of compounds and the
identification of small sub-sets that are enriched for highly
active hits. Its proprietary platform also has novel applications
in functional genomics, being able to analyse complex genetic
datasets, provide a deep understanding of pathological mechanisms
and distil actionable insights for the discovery of novel drugs,
biomarkers and diagnostics.
e-therapeutics has deployed and validated its disease-agnostic
drug discovery platform both in house and with partners, including
Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical
company.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
APPBQLLLFLLXBBV
(END) Dow Jones Newswires
March 01, 2021 02:00 ET (07:00 GMT)
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Apr 2024 to May 2024
E-therapeutics (LSE:ETX)
Historical Stock Chart
From May 2023 to May 2024